A venir
Il n’y a pas d’évènement à venir.
Archives
Novel roles for satellite cells in muscle adaptation and aging
Charlotte A. Peterson
Joseph Hamburg Endowed Professor
Director of the Center for Muscle Biology, UK College of Health Science.
More information on Charlotte A. Peterson and on her laboratory
Register by email.
Age-dependent Cardiac Dysfunction as a Mechanical Disease
Adam J. Engler
Professor and Vice-Chair of Bioengineering at UC San Diego
Resident scientist at the Sanford Consortium for Regenerative Medicine
Associate Director of the Medical-Scientist Training Program (MSTP)
Adam J. Engler is a Professor and Vice-Chair of Bioengineering at UC San Diego, where he has been on the faculty since 2008. He also is a resident scientist at the Sanford Consortium for Regenerative Medicine and Associate Director of the Medical-Scientist Training Program (MSTP).
Dr. Engler previously trained with Dr. Dennis Discher at the University of Pennsylvania, where he earned his PhD studying how ECM stiffness regulated stem cell fate. He also trained as a postdoc with Dr. Jean Schwarzbauer at Princeton University’s Department of Molecular Biology where he studied the mechanics of extracellular matrix assembly.
Dr. Engler’s current research focuses on how physical and chemical properties of the niche influence or misregulate cell function and modify genetic mechanisms of disease. In particular, his lab studies this phenomenon in the context of cardiovascular diseases and cancer. To accomplish this, his lab makes natural and synthetic matrices with unique spatiotemporal properties to mimic niche conditions, improve stem cell behavior and commitment in vitro, or direct them for therapeutic use in vivo. He currently has published over 100 manuscripts with an H-index of 52, holds 3 patents, and has a start-up company focused on stem cell research products.
Dr. Engler has received numerous awards in recognition of this research, including young investigator or mid-career awards from International Society for Matrix Biology (2008), Biomedical Engineering Society (2008), American Society of Matrix Biology (2014), American Society of Mechanical Engineering (2015), and American Society for Engineering Education (2018). Dr. Engler is a 2018 fellow of the American Institute for Biomedical Engineering and recipient of an NIH New Innovator Award grant (2009).
More information on Adam J. Engler’CV.
Register by email.
Facioscapulohumeral muscular dystrophy: a monogenic disease with marked clinical, genetic and nuclear heterogeneity
Silvère M van der Maarel, PHD
Professor of Medical Epigenetics
Chair Department of Human Genetics
Board Member Division 4
Leiden University Medical Center
Read more about the Silvère M van der Maarel
Exercise-induced myokines against muscle wasting during cancer
Rosanna Piccirillo
Head of the “Neuromuscular Dysfunctions Unit” at Mario Negri Institute for Pharmacological Research IRCCS in Milan (IRFMN), Department of Neurosciences
Read more information on Rosanna Piccirillo’s CV.
The dynamic roles of regulatory T cells in murine skeletal muscle regeneration
Diane Mathis
Professor of Immunobiology at Harvard Medical School and holder of the Morton Grove-Rasmussen chair of Immunohematology.
American National Academy of Sciences
German National Academy of Sciences
American Academy of Arts and Sciences
More information on Diane Mathis’CV.
Muscle stem cells and regenerative medicine
Shin’ichi Takeda
Director General Emeritus of Department Molecular Therapy, National Institute of Neuroscience.
National Centre of Neurology and Psychiatry.
Guest Professor in Tokushima University.
More information on Shin’Ichi Takeda’s biosktech.
Mechanistic insights from modeling cardiac features of Myotonic Dystrophy, Type 1 in mice
Tom Cooper
Professor, Baylor College of Medicine, Houston, Texas, USA, Pathology and Immunology – Molecular and Cellular Biology – Molecular Physiology and Biophysics
R. Clarence and Irene H. Fulbright Chair in Pathology
S. Donald Greenberg Chair in Pathology
Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disease caused by a CTG microsatellite repeat expansion in the DMPK gene, leading to the expression of pathogenic expanded CUG-repeat (CUGexp) containing RNA. The toxic CUGexp RNA causes disease by disrupting the activities of RNA binding proteins that regulate postnatal RNA processing ultimately resulting in expression of fetal protein isoforms of a subset of genes in adult tissues. Cardiac involvement affects 50% of individuals with DM1 primarily due to conduction abnormalities and arrhythmias causing 25% of disease-related deaths. We developed a transgenic mouse model for tetracycline-inducible and heart-specific expression of human DMPK mRNA containing 960 CUG repeats. CUGexp RNA is expressed in atria and ventricles and induced mice exhibit electrophysiological and molecular features of DM1 disease including cardiac conduction delays, spontaneous and inducible supraventricular arrhythmias, nuclear RNA foci with colocalization of the muscleblind RNA binding protein and alternative splicing defects. Importantly, both electrophysiological and molecular features were reversible upon loss of CUGexp RNA expression. The results identify potential mechanisms contributing to cardiac pathogenesis and demonstrate the utility of a reversible cardiac DM1 mouse model to facilitate development of targeted therapeutic approaches.
More information on Tom Cooper Lab’s webpage
Register by email.
Leave the guns, take the cannoli: What bimagrumab tells us about the myostatin pathway in humans
Ronenn Roubenoff
Global Head Translational Medicine Discovery & Profiling
Global Head, Musculoskeletal Translational Medicine
Novartis Institutes for Biomedical Research
Dr. Roubenoff received his MD from Northwestern University and trained in Internal Medicine and Rheumatology at the Johns Hopkins Hospital, where he was Chief Resident in Medicine. He completed concurrent fellowships in Rheumatology and in Clinical Epidemiology at Johns Hopkins, receiving a Master of Health Science degree. He then trained in Nutrition at Tufts University with Irwin Rosenberg, MD, and in Immunology with Charles Dinarello, MD. He was Chief of the Nutrition, Exercise Physiology, and Sarcopenia (NEPS) Laboratory, and Director of Human Studies at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, where he is currently Adjunct Professor of Medicine and Nutrition. Subsequently, Dr. Roubenoff became Sr. Director of Molecular Medicine at Millennium Pharmaceuticals and then Sr. Director, Immunology Research and Development, at Biogen Idec, where he led the Translational Medicine and Early Development efforts for the Immunology group. In 2009, Dr. Roubenoff was appointed Global Head of Musculoskeletal Translational Medicine at Novartis Institutes for Biomedical Research (NIBR), heading early clinical development for musculoskeletal and mobility disorders. In 2019 he was appointed Global Head of Translational Medicine Discovery & Profiling at NIBR.
Dr. Roubenoff has done pioneering work on the interactions of nutrition, exercise and hormonal and immune regulators of metabolism in aging and chronic disease, including rheumatoid arthritis, osteoarthritis, and HIV infection. He is an internationally recognized authority on sarcopenia, aging, translational medicine, and the use of biomarkers in drug development. He has published over 270 papers in the medical literature as well as writing for lay audiences. He is co-author of a New York Times Bestselling book on exercise and nutrition treatment of arthritis. Dr. Roubenoff has served on many NIH study sections, WHO committees, American Society for Nutrition Committees, Animal Care and Use and Institutional Review Committees, and as a reviewer for journals, foundations, and charities. He has won multiple awards, including membership in the Alpha Omega Alpha and Delta Omega honor societies; Fellow of the American College of Physicians and the American College of Rheumatology; the Robert H. Herman Memorial Award of the American Society for Nutrition; the American College of Rheumatology Senior Scholar Award; Tufts University Distinguished Faculty Award; Teacher of the Year at Johns Hopkins Medical School; and the Oliver Smith Award for Extraordinary Service and Caring at Tufts Medical Center.
More information on his biosketch.
Register by email.
Zoom link: https://us02web.zoom.us/j/83225875612
Nuclear membrane myopathies: Defective boundaries
Lori L Wallrath
Professor of Biochemistry, University of Iowa Healthcare
More information on Lori L Wallrath and on her laboratory
Please read her biosketch.
Measuring fatigability in clinical populations: is it relevant?
Guillaume Millet
Professor at Jean Monnet University (Saint-Etienne, France)
Leader of the ActiFS academic chair
Senior member of the Institut Universitaire de France 2019
Director of the inter-university Laboratory of Human Movement Biology in 2020
More info on Guillaume Millet’s
Website
Lab website
Twitter @kinesiologui
Summary
This seminar will start by a presentation of some recent methodological development that aims at measuring neuromuscular (NM) fatigue in clinical populations, e.g. an innovative ergometer that can switch from cycling to isometric mode within 1 s or the relevance of assessing NM fatigue in dynamic mode. Throughout examples in multiple sclerosis, cancer and Covid-19 patients, the main part of this talk will be dedicated to the discussion of the potential link between a deteriorated resistance to NM fatigue due to exercise and the subjective feeling of chronic fatigue in patients. We will conclude by showing that there is a need for tailoring training interventions to fatigue etiology (NM fatigue resistance, sleep disorders, inflammation, cardiorespiratory fitness, etc.), which further emphasizes the importance of properly determining the causes of fatigue.
Biosketch
Dr. Guillaume Millet received his PhD in Sport Sciences in 1997 and has since held various academic positions in France, including a 4-year full-time research contract at INSERM. In 2013, he moved to the University of Calgary within the Faculty of Kinesiology, where he directed a research team of ~15 trainees, the Neuromuscular Fatigue Lab. Back to France in 2018, he is now a Professor at Jean Monnet University in Saint-Etienne where he leads the ActiFS (Physical Activity, Fatigue, Health) academic chair. Dr Millet was named at the Institut Universitaire de France as a Senior member in 2019 and director of the inter-university Laboratory of Human Movement Biology (110 members) in 2020. His general research area investigates the physiological, neurophysiological and biomechanical factors associated with fatigue, both in extreme exercise and in patients (neuromuscular diseases, cancer, ICU). His research focuses on understanding fatigue in order to create tailored rehabilitation programs for clinical populations in order to enhance patients’ quality of life.